Targeting IRAK4 for Degradation with PROTACs

Area of Science:

• Immunology
• Medicinal Chemistry
• Molecular Biology

Background:

• Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) is crucial for innate immunity and its overactivation is implicated in autoimmune diseases.
• Current IRAK4 inhibitors target its kinase activity, with some progressing to clinical trials.
• Emerging evidence suggests IRAK4's scaffolding function, beyond kinase activity, may be critical in certain disease contexts.

Purpose of the Study:

• To design and synthesize a Proteolysis Targeted Chimera (PROTAC) targeting IRAK4 for degradation.
• To evaluate the efficacy of IRAK4 degradation in inhibiting cytokine production in various cell types.
• To explore novel therapeutic strategies by targeting both IRAK4 kinase and scaffolding functions.

Main Methods:

• Design and synthesis of an IRAK4-specific PROTAC (compound 9).
• Assessment of IRAK4 degradation in peripheral blood mononuclear cells (PBMCs) and human dermal fibroblasts (HDFs).
• Measurement of cytokine (IL-6, TNF-α) release in response to IL-1β stimulation.

Main Results:

• IRAK4 degradation by compound 9 effectively inhibited multiple cytokine releases in PBMCs.
• Despite successful IRAK4 degradation in IL-1β stimulated HDFs, IL-6 and TNF-α release inhibition was not observed.
• The study highlights cell-type-specific responses to IRAK4 degradation.

Conclusions:

• IRAK4 PROTAC-induced degradation offers a potential therapeutic strategy by targeting both kinase and scaffolding functions.
• The differential effects of IRAK4 degradation across cell types warrant further investigation.
• Targeting IRAK4 degradation may present new therapeutic avenues for autoimmune, inflammatory, and oncological diseases.